Autoantibodies News and Research

RSS

Long COVID antibodies induce persistent pain-like symptoms in mice

A new study coordinated by researchers at UMC Utrecht and Amsterdam UMC shows that antibodies from Long COVID patients can induce persistent pain-like symptoms in mice.

24 Mar 2026

Blood markers can indicate people at risk of developing ulcerative colitis

Researchers at örebro University have identified blood markers that can indicate who is at risk of developing ulcerative colitis - a chronic inflammatory bowel disease - later in life.

20 Feb 2026

Implantable immune scaffold predicts type 1 diabetes weeks before symptoms

The study highlights a presymptomatic phase in type 1 diabetes progression, using immune niches to track immune changes before blood sugar abnormalities.

4 Feb 2026

Umbilical cord blood markers may predict future type 1 diabetes

One day, there could be a new test to screen for type 1 diabetes, now that scientists have found markers in the blood of the umbilical cords of children who were later diagnosed with the disease.

29 Jan 2026

Redefining early detection for type 1 diabetes

Researchers have identified a protein pattern that, already at birth, looks markedly different in those who later go on to develop type 1 diabetes. The findings show that a combination of several factors during pregnancy increases the risk of the child later developing the disease. The study is published in Nature Communications and was led by researchers at Linköping University, Sweden, and the University of Florida, USA.

28 Jan 2026

Early treatment delays rheumatoid arthritis onset in high-risk individuals

Treating people who are at high risk of rheumatoid arthritis (RA) can delay the onset of the disease for several years, with benefits also continuing well after treatment has stopped.

20 Jan 2026

Landmark UK study supports nationwide screening for childhood type 1 diabetes

A landmark UK study involving tens of thousands of families has shown that childhood screening for type 1 diabetes is effective, laying the groundwork for a UK-wide childhood screening program.

20 Jan 2026

Scientists uncover promising therapeutic target for autoimmune disease affecting the brain

Scientists have identified a promising target for treatment of a devasting autoimmune disease affecting the brain.

14 Jan 2026

Gut-microbe-derived molecules may play a key role in shaping the developing immune system

An international research team has uncovered compelling evidence that gut-microbe-derived molecules may play an important role in shaping the developing immune system during early childhood.

7 Jan 2026

Researchers decipher anti-MOG antibody construction, paving way for therapies

MOG Antibody-associated Disease (MOGAD) is a rare autoimmune disease of the central nervous system. The blood of patients contains antibodies against myelin oligodendrocyte glycoprotein (MOG), a protein in the myelin layer that surrounds the neurons in the brain. It is believed that these antibodies contribute to the destruction of this protective layer in the brain.

18 Dec 2025

Genetic risk score can guide early screening for type 1 diabetes

A test using genetics to predict who is at the highest risk of developing type 1 diabetes could one day be applied to largescale health studies, to identify adults who could benefit from new drugs, new research shows.

9 Dec 2025

Single-cell RNA sequencing uncovers diverse CD4⁺ T-cell subtypes in pediatric lupus

Detailed mapping of CD4⁺ T cells from children with systemic lupus erythematosus (SLE) has revealed distinct immune cell subsets with likely roles in disease pathogenesis, according to a study led by Weill Cornell Medicine investigators.

24 Nov 2025

Breakthrough in FcγRI inhibition opens path to safer autoimmune therapies

An international research group directed by UMC Utrecht have developed and characterized two first-in-class antibodies that specifically block the high-affinity IgG receptor FcγRI.

19 Nov 2025

Blood group A linked to a higher risk of primary biliary cholangitis

Findings indicate blood group A elevates the risk of primary biliary cholangitis, suggesting ABO group analysis could aid in autoimmune liver disease diagnosis.

19 Nov 2025

Rozanolixizumab prevents congenital heart block in high-risk pregnancy

Congenital heart block, sometimes referred to as cardiac neonatal lupus, is a rare but potentially life-threatening condition that affects babies born to mothers with specific autoantibodies - called anti-SSA/Ro antibodies - which can attack the fetal heart via its electrical conduction system, leading to a slower heart rate.

22 Oct 2025

How shifting antibodies fuel aging and the new therapies aiming to slow it

This review uncovers how aging reshapes immunoglobulins, particularly IgG, IgM, and IgA, driving inflammation, cellular senescence, and tissue degeneration. By dissecting B-cell dysfunction, glycosylation changes, and Fc receptor pathways, it reveals immunoglobulins as both biomarkers and potential therapeutic targets in aging.

14 Oct 2025

Khat use linked to autoimmune hepatitis in young men

Khat (Catha edulis), a plant chewed for its stimulant effects by millions in East Africa and the Arabian Peninsula, is increasingly recognized for its hepatotoxic potential.

30 Sep 2025

Off-label drug helps one boy with autism speak, parents say. But experts want more data.

Caroline Connor's concerns about her son's development began around his 1st birthday, when she noticed he wasn't talking or using any words. Their pediatrician didn't seem worried, but the speech delay persisted. At 2½, Mason was diagnosed with autism.

26 Sep 2025

Scientists outline how future therapies could change type 1 diabetes care

Researchers writing in The Lancet review breakthroughs in type 1 diabetes treatment, from immunotherapies that delay onset to stem-cell β-cell replacement and automated insulin delivery. They stress that equitable access, validated surrogate endpoints, and scalable technologies are crucial for lasting impact.

24 Sep 2025

Oral drug baricitinib shows promise in slowing early type 1 diabetes progression

In 2023, the groundbreaking Australian BANDIT (Baricitinib in New Onset Type 1 Diabetes) trial [1] reported that a daily pill of baricitinib, commonly prescribed for rheumatoid arthritis and alopecia, could safely preserve the body's own insulin production and slow the progression of type 1 diabetes (T1D) in people recently diagnosed with the condition.

19 Sep 2025